5-fluorouracil and cardiotoxicity: a review

Jaskanwal D Sara, Jasvinder Kaur, Ryan Khodadadi, Muneeb Rehman, Ronstan Lobo, Sakti Chakrabarti, Joerg Herrmann, Amir Lerman, Axel Grothey, Jaskanwal D Sara, Jasvinder Kaur, Ryan Khodadadi, Muneeb Rehman, Ronstan Lobo, Sakti Chakrabarti, Joerg Herrmann, Amir Lerman, Axel Grothey

Abstract

Fluoropyrimidines such as 5-fluorouracil (5-FU) form the foundation of a wide variety of chemotherapy regimens. 5-FU is in fact the third most commonly used chemotherapeutic agent in the treatment of solid malignancies across the world. As with all chemotherapy, balancing the potential benefits of therapy against the risks of drug-related toxicity is crucial when clinicians and patients make shared decisions about treatment. 5-FU is the second most common chemotherapeutic drug associated with cardiotoxicity after anthracyclines, which can manifest as chest pain, acute coronary syndrome/myocardial infarction or death. Nevertheless a widespread appreciation of 5-FU-related cardiotoxicity and its implications is lacking amongst clinicians. In this review, we outline the incidence, possible risk factors, and likely pathophysiological mechanisms that may account for 5-FU-related cardiotoxicity and also highlight potential management strategies for this poorly understood clinical entity.

Keywords: 5-fluorouracil; cardiotoxicity; chemotherapy; coronary vasospasm; fluoropyrimidine.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Diagram outlining the two potential mechanisms by which 5-fluorouracil could lead to cardiotoxicity: direct cellular damage and ischemia. 5-FU, 5-fluorouracil; DPD, dihydropyrimidine dehydrogenase; NO, nitric oxide; RBC, red blood cell; vWF, von Willebrand factor. *Takatsubo cardiomyopathy is typically seen as a structural cardiomyopathic process, though there is some evidence which suggests that ischemia may contribute to the pathophysiology of this process. This remains a controversial area that requires further investigation.
Figure 2.
Figure 2.
Flow diagram demonstrating a suggested treatment approach for patients who have experienced suspected cardiotoxicity related to 5-fluorouracil chemotherapy. 5-FU, 5-fluorouracil; CAD, coronary artery disease; CCB, calcium channel blocker. *When significant CAD has not been demonstrated clinicians could consider invasive pharmacologic provocation testing to identify reproducible coronary vasospasm, though this should only be undertaken by experienced operators in appropriately resourced centers.

References

    1. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000; 18: 299–313.
    1. Myers CE. The pharmacology of the fluoropyrimidines. Pharmacol Rev 1981; 33: 1–15.
    1. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28: 374–378.
    1. Labianca R, Beretta G, Clerici M, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505–510.
    1. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795–1801.
    1. Lestuzzi C, Vaccher E, Talamini R, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol 2014; 25: 1059–1064.
    1. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 2010; 40: 303–307.
    1. Hrovatin E, Viel E, Lestuzzi C, et al. Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin. J Cardiovasc Med (Hagerstown) 2006; 7: 637–640.
    1. Talapatra K, Rajesh I, Rajesh B, et al. Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil. J Cancer Res Ther 2007; 3: 169–171.
    1. Calik AN, Celiker E, Velibey Y, et al. Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. Am J Emerg Med 2012; 30: 257.e1–e3.
    1. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993; 71: 493–509.
    1. Manojlovic N, Babic D, Stojanovic S, et al. Capecitabine cardiotoxicity–case reports and literature review. Hepatogastroenterology 2008; 55: 1249–1256.
    1. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134: 75–82.
    1. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8: 191–202.
    1. Kwakman JJ, Simkens LH, Mol L, et al. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer 2017; 76: 93–99.
    1. Polk A, Shahmarvand N, Vistisen K, et al. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open 2016; 6: e012798.
    1. Khan MA, Masood N, Husain N, et al. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc 2012; 62: 430–434.
    1. Koca D, Salman T, Unek IT, et al. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy 2011; 57: 381–387.
    1. Salepci T, Seker M, Uyarel H, et al. 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels. Med Oncol 2010; 27: 416–420.
    1. Holubec L, Jr, Topolcan O, Finek J, et al. Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients–a pilot study. Anticancer Res 2007; 27: 1883–1886.
    1. Yilmaz U, Oztop I, Ciloglu A, et al. 5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring. Int J Clin Pract 2007; 61: 795–801.
    1. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58: 487–493.
    1. Tsibiribi P, Descotes J, Lombard-Bohas C, et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer 2006; 93: E27–E30.
    1. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005; 41: 1542–1546.
    1. Ceyhan C, Meydan N, Barutca S, et al. Ultrasound tissue characterization by integrated backscatter for analyzing Fluorouracil induced myocardial damage. Echocardiography 2005; 22: 233–238.
    1. Meydan N, Kundak I, Yavuzsen T, et al. Cardiotoxicity of de Gramont’s regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 2005; 35: 265–270.
    1. Sudhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004; 15: 661–664.
    1. Oztop I, Gencer M, Okan T, et al. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol 2004; 34: 262–268.
    1. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–2292.
    1. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097–4106.
    1. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759–1768.
    1. Balloni L, Porta C, Rossi S, et al. Left ventricular function in colon cancer patients receiving adjuvant fluoro-folate chemotherapy: an echocardiographic study. Oncol Rep 2000; 7: 887–890.
    1. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–493.
    1. Orditura M, De Vita F, Sarubbi B, et al. Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients. Oncol Rep 1998; 5: 645–647.
    1. Weidmann B, Jansen W, Heider A, et al. 5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. Am J Cardiol 1995; 75: 194–195.
    1. Gradishar W, Vokes E, Schilsky R, et al. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol 1991; 19: 8–15.
    1. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993; 33: 1060–1070.
    1. Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993; 72: 2242–2247.
    1. Jeremic B, Jevremovic S, Djuric L, et al. Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin. J Chemother 1990; 2: 264–267.
    1. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7: 509–514.
    1. Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 1990; 29: 1001–1003.
    1. Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 1988; 13: 41–46.
    1. Pottage A, Holt S, Ludgate S, et al. Fluorouracil cardiotoxicity. Br Med J 1978; 1: 547.
    1. Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993; 50: 441–444.
    1. Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 2003; 65: 108–112.
    1. Jensen SA, Hasbak P, Mortensen J, et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010; 28: 5280–5286.
    1. Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17: 729–736.
    1. Becker K, Erckenbrecht JF, Haussinger D, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57: 475–484.
    1. Yung LT, McCrea WA. Capecitabine induced acute coronary syndrome. BMJ Case Rep 2009. DOI: 10.1136/bcr.09.2008.0964.
    1. Basselin C, Fontanges T, Descotes J, et al. 5-Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy 2011; 31: 226.
    1. Tajik R, Saadat H, Taherkhani M, et al. Angina induced by 5-fluorouracil infusion in a patient with normal coronaries. Am Heart Hosp J 2010; 8: E111–E112.
    1. Camaro C, Danse PW, Bosker HA. Acute chest pain in a patient treated with capecitabine. Neth Heart J 2009; 17: 288–291.
    1. Atar A, Korkmaz ME, Ozin B. Two cases of coronary vasospasm induced by 5-fluorouracil. Anadolu Kardiyol Derg 2010; 10: 461–462.
    1. Alter P, Herzum M, Soufi M, et al. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006; 4: 1–5.
    1. Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control 2004; 11: 46–49.
    1. Luwaert RJ, Descamps O, Majois F, et al. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J 1991; 12: 468–470.
    1. Heistad DD, Armstrong ML, Marcus ML, et al. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 1984; 54: 711–718.
    1. Lopez JA, Armstrong ML, Piegors DJ, et al. Effect of early and advanced atherosclerosis on vascular responses to serotonin, thromboxane A2, and ADP. Circulation 1989; 79: 698–705.
    1. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168–175.
    1. Reddy KG, Nair RN, Sheehan HM, et al. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994; 23: 833–843.
    1. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948–954.
    1. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491–497.
    1. Schwartz BG, Economides C, Mayeda GS, et al. The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. Int J Impot Res 2010; 22: 77–90.
    1. Hasdai D, Cannan CR, Mathew V, et al. Evaluation of patients with minimally obstructive coronary artery disease and angina. Int J Cardiol 1996; 53: 203–208.
    1. Hasdai D, Gibbons RJ, Holmes DR, Jr, et al. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 1997; 96: 3390–3395.
    1. Hasdai D, Holmes DR, Jr, Higano ST, et al. Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc 1998; 73: 1133–1140.
    1. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol 2005; 568: 357–369.
    1. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028–3033.
    1. Kleiman NS, Lehane DE, Geyer CE, Jr, et al. Prinzmetal’s angina during 5-fluorouracil chemotherapy. Am J Med 1987; 82: 566–568.
    1. Burger AJ, Mannino S. 5-Fluorouracil-induced coronary vasospasm. Am Heart J 1987; 114: 433–436.
    1. Mizuno Y, Hokamura Y, Kimura T, et al. A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction. Jpn Circ J 1995; 59: 303–307.
    1. Freeman NJ, Costanza ME. 5-Fluorouracil-associated cardiotoxicity. Cancer 1988; 61: 36–45.
    1. Henry PD, Yokoyama M. Supersensitivity of atherosclerotic rabbit aorta to ergonovine. Mediation by a serotonergic mechanism. J Clin Invest 1980; 66: 306–313.
    1. Kim SM, Kwak CH, Lee B, et al. A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. Korean J Intern Med 2012; 27: 342–345.
    1. Spencker S, Schmittel A, Westermann D, et al. [Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil]. Internist (Berl) 2007; 48: 69–72, 74.
    1. Sara JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv 2015; 8: 1445–1453.
    1. Thyss A, Gaspard MH, Marsault R, et al. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol 1992; 3: 88.
    1. Kinhult S, Albertsson M, Eskilsson J, et al. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning 2001; 23: 1–8.
    1. Cwikiel M, Zhang B, Eskilsson J, et al. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 1995; 9: 561–576.
    1. Jensen SA, Sorensen JB. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol 2012; 69: 57–64.
    1. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–978.
    1. Schalkwijk CG, Poland DC, van Dijk W, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351–357.
    1. Spasojevic I, Maksimovic V, Zakrzewska J, et al. Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and functioning. J Chem Inf Model 2005; 45: 1680–1685.
    1. Spasojevic I, Jelic S, Zakrzewska J, et al. Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia. Molecules 2008; 14: 53–67.
    1. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006; 25: 305–309.
    1. Kinhult S, Albertsson M, Eskilsson J, et al. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol 2003; 42: 304–308.
    1. Lamberti M, Porto S, Marra M, et al. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res 2012; 31: 60.
    1. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980; 30: 871–879.
    1. Millart H, Brabant L, Lorenzato M, et al. The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart. Anticancer Res 1992; 12: 571–576.
    1. Tamatsu H, Nakazawa M, Imai S, et al. 31P-topical nuclear magnetic resonance (31P-TMR) studies of cardiotoxic effects of 5-fluorouracil (5-FU) and 5’-deoxy-5-fluorouridine (5’-DFUR). Jpn J Pharmacol 1984; 34: 375–379.
    1. Durak I, Karaayvaz M, Kavutcu M, et al. Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A 2000; 59: 585–589.
    1. Muneoka K, Shirai Y, Yokoyama N, et al. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. Int J Clin Oncol 2005; 10: 441–443.
    1. Arellano M, Malet-Martino M, Martino R, et al. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 1998; 77: 79–86.
    1. Guo XD, Harold N, Saif MW, et al. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmacol 2003; 52: 79–85.
    1. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47–51.
    1. Maring JG, van Kuilenburg AB, Haasjes J, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002; 86: 1028–1033.
    1. Shahrokni A, Rajebi MR, Saif MW. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: a challenge or a dilemma? Clin Colorectal Cancer 2009; 8: 231–234.
    1. Sasson Z, Morgan CD, Wang B, et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 1994; 10: 861–864.
    1. Kuropkat C, Griem K, Clark J, et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 1999; 22: 466–470.
    1. Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987; 294: 238–243.
    1. Grunwald MR, Howie L, Diaz LA., Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol 2012; 30: e11–e14.
    1. Kwakman JJ, Simkens LH, Mol L, et al. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer 2017; 76: 93–99.
    1. Thyss A, Milano G, Schneider M, et al. Circulating drug levels in patients presenting cardiotoxicity to 5-FU. Eur J Cancer Clin Oncol 1988; 24: 1675–1676.
    1. Clasen SC, Ky B, O’Quinn R, et al. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol 2017; 8: 970–979.
    1. Polk A, Vaage-Nilsen M, Vistisen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013; 39: 974–984.
    1. Reriani M, Sara JD, Flammer AJ, et al. Coronary endothelial function testing provides superior discrimination compared with standard clinical risk scoring in prediction of cardiovascular events. Coron Artery Dis 2016; 27: 213–220.
    1. Osto E, Coppolino G, Volpe M, et al. Restoring the dysfunctional endothelium. Curr Pharm Des 2007; 13: 1053–1068.
    1. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e663–e828.
    1. Saif MW, Garcon MC, Rodriguez G, et al. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series. In Vivo 2013; 27: 531–534.
    1. Cianci G, Morelli MF, Cannita K, et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003; 88: 1507–1509.
    1. Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann Oncol 2014; 25: 117–121.
    1. Bozkurt O, Karaca H, Ciltas A, et al. Efficacy and safety of raltitrexed combinations with uracil-tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO). Asian Pac J Cancer Prev 2014; 15: 1845–1849.
    1. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671–8678.
    1. Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768–3774.
    1. Kikuchi K, Majima S, Murakami M. [Clinical survey on cardiotoxicity of tegafur (FT-207)–compilation of a nationwide survey]. Gan To Kagaku Ryoho 1982; 9: 1482–1488.
    1. Marsh JC, Catalano P, Huang J, et al. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer 2002; 2: 43–50.
    1. Nagashima F, Ohtsu A, Yoshida S, et al. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 2005; 8: 6–11.
    1. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58: 191–197.
    1. Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99: 584–590.
    1. Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. Cancer Chemother Pharmacol 1999; 43: 157–161.
    1. Ambrosy AP, Kunz PL, Fisher GA, et al. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol 2012; 110: 1623–1626.
    1. Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am J Med 1988; 85: 750–751.
    1. Klubes P, Cerna I, Meldon MA. Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 1982; 8: 17–21.
    1. Ma WW, Saif MW, El-Rayes BF, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer 2017; 123: 345–356.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する